Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The lung cancer paradox: time for action.

× No keyword cloud information.

31 in total

1. A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

Authors: J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau
Journal: N Engl J Med Date: 1992-12-03 Impact factor: 91.245

2. Resection rates and postoperative mortality in 7,899 patients with lung cancer.

Authors: R A Damhuis; P R Schütte
Journal: Eur Respir J Date: 1996-01 Impact factor: 16.671

3. Pulmonary infiltration after exposure to home renovation dust: histopathology and microanalysis.

Authors: K Anderson; C P McSharry; G P Morris; C H Cameron; D McLellan; D R Vernon
Journal: Thorax Date: 1996-06 Impact factor: 9.139

Review 4. Management of lung cancer.

Authors: M F Muers; R A Haward
Journal: Thorax Date: 1996-06 Impact factor: 9.139

5. Chemotherapy in non-small cell lung cancer. Large trial will reduce uncertainty. Steering Committee of the Big Lung Trial.

Authors: R J Stephens; M K Parmar; R L Souhami; S Spiro
Journal: BMJ Date: 1996-01-27

6. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants.

Authors: K Osterlind; H H Hansen; M Hansen; P Dombernowsky; P K Andersen
Journal: J Clin Oncol Date: 1986-09 Impact factor: 44.544

7. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.

Authors: W K Hong; C Nicaise; R Lawson; J A Maroun; R Comis; J Speer; D Luedke; M Hurtubise; V Lanzotti; J Goodlow
Journal: J Clin Oncol Date: 1989-04 Impact factor: 44.544

8. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.

Authors: J R Jett; L Everson; T M Therneau; J E Krook; R J Dalton; R F Marschke; M H Veeder; S F Brunk; J A Mailliard; D I Twito
Journal: J Clin Oncol Date: 1990-01 Impact factor: 44.544

9. The National Cancer Data Base report on lung cancer.

Authors: W A Fry; H R Menck; D P Winchester
Journal: Cancer Date: 1996-05-01 Impact factor: 6.860

10. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.

Authors: M L Slevin; L Stubbs; H J Plant; P Wilson; W M Gregory; P J Armes; S M Downer
Journal: BMJ Date: 1990-06-02